Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 8

1.

Off-label drug use and promotion: balancing public health goals and commercial speech.

Kesselheim AS.

Am J Law Med. 2011;37(2-3):225-57. No abstract available.

PMID:
21847880
2.

Recent developments in direct consumer advertising of attention disorder stimulants and creating limits to withstand constitutional scrutiny.

Strawn MN.

J Contemp Health Law Policy. 2003 Spring;19(2):495-520. Review. No abstract available.

PMID:
14748255
3.

Regulation of prescription drug promotion: direct-to-consumer advertising.

Baylor-Henry M, Drezin NA.

Clin Ther. 1998;20 Suppl C:C86-95. Review.

PMID:
9915094
4.

The Food and Drug Administration's regulation of drug labeling, advertising, and promotion: looking back and looking ahead.

Hayes TA.

Clin Pharmacol Ther. 1998 Jun;63(6):607-16. Review. No abstract available.

PMID:
9663174
5.

Direct-to-consumer prescription drug advertising.

Terzian TV.

Am J Law Med. 1999;25(1):149-67. Review. No abstract available.

PMID:
10207573
6.

Review of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act: What can the obstetric community learn from the pediatric experience?

Ren Z, Zajicek A.

Semin Perinatol. 2015 Nov;39(7):530-1. doi: 10.1053/j.semperi.2015.08.006. Epub 2015 Oct 9. Review.

7.

Off-label use of drugs in children.

Frattarelli DA, Galinkin JL, Green TP, Johnson TD, Neville KA, Paul IM, Van Den Anker JN; American Academy of Pediatrics Committee on Drugs..

Pediatrics. 2014 Mar;133(3):563-7. doi: 10.1542/peds.2013-4060. Epub 2014 Feb 24. Review.

8.

The complexity of covering off-label use for a multitude of oncology regimens.

Mehr SR.

Am J Manag Care. 2012 Dec;18(5 Spec No.):SP242-7. Review. No abstract available.

Supplemental Content

Support Center